Cipla faces headwinds but remains resilient with strong product portfolio, robust earnings growth potential, and reasonable ...

Cipla's Patalganga plant manufactures active pharmaceutical ingredients (APIs), the key raw materials for medicines, as well as formulations. The US drug regulator had conducted a routine current ...

MUMBAI/BENGALURU (Reuters) - Tariffs should not influence decisions at Indian drug companies, Cipla's top executive ... will make to us... and will not justify relocating our manufacturing ...